Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Journal of Cardiovascular Pharmacology and Therapeutics|April 8, 2015
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo StudiesElisabeth Perzborn, Stefan Heitmeier, Volker Laux
Annals of the New York Academy of Sciences|March 26, 2011
The discovery and development of rivaroxabanFrank Misselwitz, Scott D Berkowitz, Elisabeth Perzborn
Frontiers in Pharmacology|December 11, 2013
The discovery of rivaroxaban: translating preclinical assessments into clinical practiceDagmar Kubitza, Elisabeth Perzborn, Scott D Berkowitz
Thrombosis Research|February 18, 2014
Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitroElisabeth Perzborn, Stefan Heitmeier, Volker Laux, et al.
Seminars in Thrombosis and Hemostasis|July 17, 2007
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitorVolker Laux, Elisabeth Perzborn, Dagmar Kubitza, et al.
Nature Reviews. Drug Discovery|December 18, 2010
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitorElisabeth Perzborn, Susanne Roehrig, Alexander Straub, et al.
British Journal of Pharmacology|January 30, 2002
Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studiesJohannes-Peter Stasch, Klaus Dembowsky, Elisabeth Perzborn, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 9, 2010
Rivaroxaban: a new oral factor Xa inhibitorElisabeth Perzborn, Susanne Roehrig, Alexander Straub, et al.
Stroke|January 24, 2013
Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxabanWei Zhou, Markus Zorn, Peter Nawroth, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 9, 2013
Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro studyMareike Kristina Körber, Elisabeth Langer, Sabine Ziemer, et al.
Pageof 3